|
- Efficacy of Bempedoic Acid, Novel Treatment for Elevated LDL . . .
By Anthony Rice Bempedoic acid is a novel non-statin drug produced by Esperion Therapeutics to treat hypercholesterolemia, elevated levels of low-density lipoprotein (LDL) cholesterol in the blood 1 In the double-blind, placebo-controlled, phase 3 2022 CLEAR Outcomes trial conducted by Esperion, bempedoic acid treatment was associated with reductions in major adverse cardiovascular events
- Bempedoic Acid: The Statin Alternative for Lowering Cholesterol
Learn how bempedoic acid lowers cholesterol without the muscle side effects of statins See who it's for, how it works, and clinical trial results
- Bempedoic Acid: Lipid Lowering for Cardiovascular Disease . . .
Bempedoic acid is a novel, oral, non-statin lipid-l owering therapy that works by inhibiting adenosine triphosphate-citrate lyase, an enzymatic reaction upstream of 3-hydroxy-3-methylglutaryl coenzyme A reductase in the hepatic cholesterol synthesis pathway
- Comparative Cardiovascular Benefits of Bempedoic Acid and . . .
In the CLEAR (Cholesterol Lowering via Bempedoic Acid, an ACL-Inhibiting Regimen) Outcomes trial, treatment of statin-intolerant patients with bempedoic acid produced a 21% decrease in low-density lipoprotein cholesterol (LDL-C) relative to placebo and a 13% relative reduction in the risk of major adverse cardiovascular events
- Reshaping Dyslipidaemia Treatment with Bempedoic Acid—A . . .
Apolipoprotein B, total cholesterol, and non-HDL-C were also reduced, particularly in the combination therapy, while hsCRP was reduced particularly in the monotherapy group with 180 mg bempedoic acid (40%) [32]
- Bempedoic acid in the management of lipid disorders and . . .
Bempedoic acid, the first in-class inhibitor of ATP-citrate lyase presents a new approach to lipid-lowering therapy By reducing the endogenous production of cholesterol, upstream of the rate-limiting enzyme HMG-CoA-reductase, i e , the target of statins, bempedoic acid reduces circulating plasma concentrations of low-density lipoprotein cholesterol (LDL-C), and major adverse CVD events (MACE
- PATIENT-CENTERED EDUCATION FROM THE NATIONAL LIPID . . .
Bempedoic acid interferes with an enzyme in the liver that regulates cholesterol production It allows for increased clearance of LDL-C from the blood stream leading to lower levels Bempedoic acid is only active within the liver cells and not in skeletal muscle Therefore, it can be used in patients who have had prior statin associated muscle symptoms
- (PDF) Bempedoic Acid: A Novel Approach in Managing . . .
This review concludes that bempedoic acid represents a significant advancement in lipid-lowering therapy, offering a valuable option for patients with hypercholesterolemia, particularly those with
|
|
|